Last reviewed · How we verify
NCT01001468
A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis
Phase 2 trial testing VB-201 in Active Plaque Psoriasis in 185 participants. Completed in 1 July 2011.
1 July 2011
Quick facts
| Lead sponsor | Vascular Biogenics Ltd. operating as VBL Therapeutics |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 185 |
| Start date | 1 December 2009 |
| Primary completion | 1 July 2011 |
| Estimated completion | 1 July 2011 |
| Sites | 18 locations across United States, Germany, Israel |
Drugs / interventions tested
Conditions studied
- Active Plaque Psoriasis — all drugs for Active Plaque Psoriasis →
Sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics — full company profile →
Who can join
Adults 18 to 75, any sex, with Active Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Improvement in the Psoriasis Area and Severity Index(PASI 75)from baseline at Week 12
Time frame: 20 weeks
Sponsor's own description
The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
Mease PJ, Armstrong AW. · · 2014 · cited 167× · PMID 24566842 · DOI 10.1007/s40265-014-0191-y -
Small Molecule NF-κB Pathway Inhibitors in Clinic.
Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164
Verify or expand the search:
- PubMed search for NCT01001468
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of VB-201
Trials testing the same drug.
- NCT04939311 — Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial · Phase 1, PHASE2 · withdrawn
Other Vascular Biogenics Ltd. operating as VBL Therapeutics trials
Trials by the same sponsor.
- NCT04733833 — A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 · Phase 2 · completed
- NCT03398655 — A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL) · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01001468 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vascular Biogenics Ltd. operating as VBL Therapeutics
- Last refreshed: 15 November 2011
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01001468.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing